This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up
by Zacks Equity Research
Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.
Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
by Zacks Equity Research
Apellis (APLS) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
by Zacks Equity Research
Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by higher Exparel sales.
Philips (PHG) Q2 Earnings Rise, Revenues Fall Year Over Year
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from strong momentum across the Diagnosis & Treatment, Connected Care and Personal Health businesses.
Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Akero Therapeutics (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
by Zacks Equity Research
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.
Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
by Zacks Equity Research
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
by Zacks Equity Research
Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
by Zacks Equity Research
Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Akero Therapeutics, Inc. (AKRO) points to a 58.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.
Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?
by Zacks Equity Research
Here is how GSK (GSK) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Akero Therapeutics, Inc. (AKRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and Perspective Therapeutics (CATX) have performed compared to their sector so far this year.
Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback
by Ekta Bagri
Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.
Akero (AKRO) Slumps 63% on Mixed Results From NASH Study
by Zacks Equity Research
Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.
Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA
by Zacks Equity Research
Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.
Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study
by Zacks Equity Research
Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.
Apellis (APLS) Stock Surges 62% in 6 Months: Here's Why
by Zacks Equity Research
Apellis' (APLS) shares have rallied 62% over the past six months due to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake of its first marketed product, Empaveli, has further bolstered the stock value.
Acadia (ACAD) Expands Existing Licensing Deal With Neuren
by Zacks Equity Research
Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidate.